| Symbol | HELP |
|---|---|
| Name | CYBIN INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 100 KING STREET WEST,SUITE 5600, TORONTO, M5X 1C9, Canada |
| Telephone | +1 908 764-8385 |
| Fax | — |
| — | |
| Website | https://www.helus.com/ |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001833141 |
| Description | Cybin is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders, all protected under its ever-growing IP portfolio. Additional info from NASDAQ: |
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
Read moreHelus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
Read moreNew Form SCHEDULE 13G/A - CYBIN INC. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000919574-26-003491 <b>Size:</b> 12 KB
Read moreNew Form SCHEDULE 13G - CYBIN INC. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000919574-26-003218 <b>Size:</b> 15 KB
Read moreHelus Pharma to Participate at the 29th Annual Milken Institute Global Conference
Read more